- Home
- EQR vs ILMN Comparison
EQR vs ILMN Comparison
Compare EQR & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQR | ILMN |
|---|---|---|
| Founded | 1993 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5B | 18.9B |
| IPO Year | 1993 | 2000 |
Fundamental Metrics
Financial Performance| Metric | EQR | ILMN |
|---|---|---|
| Price | $62.73 | $135.32 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 16 |
| Target Price | $70.00 | ★ $117.31 |
| AVG Volume (30 Days) | ★ 2.2M | 1.7M |
| Earning Date | 02-02-2026 | 02-05-2026 |
| Dividend Yield | ★ 4.44% | N/A |
| EPS Growth | ★ 24.49 | N/A |
| EPS | 3.03 | ★ 4.46 |
| Revenue | $3,078,827,000.00 | ★ $4,288,000,000.00 |
| Revenue This Year | $5.10 | N/A |
| Revenue Next Year | $3.51 | $2.24 |
| P/E Ratio | ★ $20.55 | $30.53 |
| Revenue Growth | ★ 4.69 | N/A |
| 52 Week Low | $58.38 | $68.70 |
| 52 Week High | $75.86 | $153.06 |
Technical Indicators
Market Signals| Indicator | EQR | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 61.82 | 62.29 |
| Support Level | $60.89 | $129.29 |
| Resistance Level | $62.52 | $138.80 |
| Average True Range (ATR) | 0.98 | 3.96 |
| MACD | 0.19 | -0.36 |
| Stochastic Oscillator | 91.28 | 71.84 |
Price Performance
Historical ComparisonAbout EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 312 apartment communities with over 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.